Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Drug for Dust Mite Allergy Approved by FDA

XTALKS VITALS NEWS

Dust Mite

Dust mites are microscopic insects which are commonly found in soft furnishings – like carpets, bedding and other furniture – in the home.

Share this!

March 3, 2017 | by Sarah Hand, M.Sc.

Good news for house dust mite allergy sufferers: the FDA has approved Merck, Sharp & Dohme Corp.’s Odactra to treat allergic rhinitis and conjunctivitis in patients between the ages of 18 and 65. The allergen extract is the first of its kind to be administered sublingually.

“House dust mite allergic disease can negatively impact a person's quality of life,” said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. “The approval of Odactra provides patients an alternative treatment to allergy shots to help address their symptoms.”

Dust mites are microscopic insects which are commonly found in soft furnishings – like carpets, bedding and other furniture – in the home. Symptoms of a dust mite allergy include a runny nose, cough, nasal congestion and watery eyes.



Odactra uses allergen immunotherapy to expose patients to dust mite allergens. By introducing a small amount of these allergens to the immune system on a regular basis, the hope is that the symptoms of the allergy will gradually be reduced.

The drug is taken once-per-day in a dissolvable pill placed under the tongue. Patients take their first dose of Odactra in the presence of a physician in the event that the drug triggers any adverse reactions. Eight to 14 weeks of daily dosing may be necessary before a patient begins to see an improvement in their allergy symptoms.

Multiple clinical trials involving approximately 2,500 participants in Canada, the US and Europe were conducted to assess the safety and efficacy of Odactra. In these trials, patients taking Odactra saw a 16 to 18 percent reduction in their allergy systems and the need to take antihistamines, compared to patients given a placebo.

As a condition of the approval, the FDA is requiring that the drug carry a boxed warning to alert prescribing physicians and patients to the risk of serious, potentially-fatal, allergic reactions. The FDA also requires the patients taking Odactra be prescribed an epinephrine auto-injector in case of adverse reactions.


Keywords: Allergy, FDA, Drug Delivery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.